| Literature DB >> 32301836 |
Joseph T S Low1, Sarah Davis1, Lynda Greenslade2, Cathy Carroll3, Rachel Craig3, Jo Wilson3, Jennifer-Louise Clancy2, Aileen Marshall2,4, Douglas Thorburn2,4, Patrick Stone1.
Abstract
BACKGROUND AND AIMS: Liver health professionals have difficulty discussing liver cirrhosis and its prognosis with patients and families. Question Prompt Lists (QPLs), which are evidence-based lists of "recommended questions," may improve communication but need to be designed specifically for the target population. This study aimed to develop and pilot a QPL for patients with cirrhosis.Entities:
Mesh:
Year: 2020 PMID: 32301836 PMCID: PMC7664949 DOI: 10.1097/MCG.0000000000001347
Source DB: PubMed Journal: J Clin Gastroenterol ISSN: 0192-0790 Impact factor: 3.174
Participant Demographic Details—Online Survey, Semistructured Interviews (Phase 1)
| Online Survey | n (%) |
|---|---|
| Patient | N=78 |
| Age range (y) | |
| 18-34 | 4 (5) |
| 35-44 | 8 (10) |
| 45-54 | 19 (25) |
| 55-64 | 28 (36) |
| 65-74 | 15 (19) |
| >75 | 4 (5) |
| Ethnicity | |
| White—UK | 71 (91) |
| White—other | 6 (7.5) |
| Mixed—white UK/African | 1 (1.5) |
| Gender | |
| Male | 27 (35) |
| Female | 51 (65) |
| Cause of cirrhosis | |
| Autoimmune (PBC, AIH, PSC) | 42 (54) |
| Nonalcohol fatty liver disease | 14 (18) |
| Alcohol-related liver disease | 10 (13) |
| Viral (HBV/HCV) | 3 (4) |
| Other (hemochromatosis, Budd-Chiari, SCS, cryptogenic) | 5 (6) |
| Unknown | 4 (5) |
| Patient | N=12 |
| Age | |
| Mean (SD) | 51 (11) |
| Minimum-maximum | 31-69 |
| Gender | |
| Male | 8 (67) |
| Female | 4 (33) |
| Ethnicity | |
| White—UK | 7 (58) |
| White—other | 3 (25) |
| South Asian | 1 (7.5) |
| Other | 1 (7.5) |
| Cause of cirrhosis | |
| Alcohol-related liver disease | 6 (50) |
| NASH/NAFLD | 2 (50) |
| Hepatitis C | 1 (3) |
| Unknown | 3 |
| Close family member | N=6 |
| Relationship status | |
| Parent | 3 |
| Son | 2 |
| Spouse | 1 |
| Gender | |
| Male | 3 (50) |
| Female | 3 (50) |
| Ethnicity | |
| White—UK | 6 (100) |
| Cause of patient cirrhosis | |
| Alcohol-related liver disease | 3 (50) |
| NASH | 1 (17) |
| Unknown | 2 (33) |
| Health professional | |
| Profession | |
| Consultant hepatologist | 5 |
| Registrar/clinical fellow | 2 |
| Transplant nurse coordinators | 4 |
| Clinical nurse specialist | 1 |
| Alcohol liaison nurse | 1 |
| Dietician | 1 |
| Gender | |
| Male | 6 (43) |
| Female | 8 (57) |
| Ethnicity | |
| White—UK | 12 (86) |
| Black—UK | 1 (12) |
| South Asian | 1 (12) |
AIH indicates autoimmune hepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SCS, secondary bilary cirrhosis.
Participant Demographic Detail—Pilot Study (Phase 3)
| n (%) | |
|---|---|
| Total sample | N=133 |
| Age | |
| Mean (SD) | 62 (12) |
| Minimum-maximum | 27-85 |
| Gender | |
| Male | 77 (62) |
| Female | 47 (38) |
| Ethnicity | |
| White—UK | 71 (57) |
| White—other | 19 (15) |
| South Asian | 17 (14) |
| Other | 8 (6) |
| Missing | |
| Cause of cirrhosis where recorded | N=125 |
| ARLD | 63 (47) |
| NASH/NAFLD | 21 (16) |
| Autoimmune (PSC/PBC/AIH) | 18 (14) |
| Viral (HBV/HCV) | 12 (9) |
| HCC | 1 (1) |
| Cryptogenic | 2 (2) |
| Portal hyper/HV+SV thrombosis | 3 (2) |
| Mixed | 5 (4) |
| Missing | 8 (6) |
| QPL users | N=67 |
| Age | |
| Mean (SD) | 63 (10) |
| Minimum-maximum | 35-85 |
| Gender | |
| Male | 43 (64) |
| Female | 24 (36) |
| Ethnicity | |
| White—UK | 37 (55) |
| White—European | 11 (17) |
| South Asian | 12 (18) |
| Other | 3 (4) |
| Missing | 4 (6) |
| Cause of cirrhosis | |
| ARLD | 25 (37) |
| NASH/NAFLD | 13 (19) |
| Viral (HBV/HCV) | 9 (13) |
| Autoimmune (PSC/PBC/AIH) | 11 (16) |
| HCC | 1 (1) |
| Heme/ARLD | 1 (1) |
| NASH/ARLD | 2 (3) |
| HV thrombosis | 1 (1) |
| Missing | 4 (6) |
AIH indicates autoimmune hepatitis; ARLD, alcohol-related liver disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HV, hepatic vein; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; QPL, Question Prompt List; SV, splenic vein.
FIGURE 1Patient recruitment and use of QPL. OP indicates outpatient; QPL, Question Prompt List.
Frequency of Questions Asked From the Question Prompt List (n=66)
| Questions Asked | Total |
|---|---|
| What is my life expectancy | 21 |
| What symptoms should I look out for? | 19 |
| What is my treatment plan (short term/long term)? | 19 |
| Is there any special diet that I shall follow? | 12 |
| How can I improve my liver function? | 12 |
| Can I travel abroad? | 12 |
| What is the side effect of my medication | 10 |
| What can I expect from the future? | 10 |
| Support hub | 10 |
| What do my test results mean? | 9 |
| Can I have occasional alcohol/low alcohol? | 8 |
| What should I do if symptoms occur? | 7 |
| What is cirrhosis | 6 |
| Can I drive? | 6 |
| What is liver disease | 5 |
| I am feeling worried/low. Where can I get help? | 5 |
| Will liver disease affect my ability to work? | 4 |
| What is my liver medication trying to achieve | 4 |
| What is my liver medication trying to achieve? | 4 |
| I am concerned about my sex life | 4 |
| Can you review my liver medication? | 4 |
| Why do I have liver disease | 3 |
| Wills | 1 |
| Will liver cancer spread to other parts of the body? | 1 |
| What is the cause of liver disease | 1 |
| What are the success of the operation | 1 |
| Is she going to develop HE again? | 1 |
| How quick would her deterioration be at the EOL? | 1 |
| Help at home | 1 |
| Effects on breathing difficulties | 1 |
| Carvedhiol supply | 1 |
| Can she get some bereavement support or counseling? | 1 |
| Effects of other medication on liver? | 1 |
EOL indicates end of life; HE, hepatic encephalopathy.